Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564162 | 0.84 | CNR1 (0.42) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL2828152 | 0.82 | GABRA1 (0.55) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL3569245 | 0.77 | KMT2A (0.53) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL8802795 | 0.75 | KMT2A (0.54) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL7271469 | 0.72 | KMT2A (1.00) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL3988229 | 0.69 | KMT2A (0.60) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL9266008 | 0.69 | KMT2A (0.68) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL2823564 | 0.68 | GABRG2 (0.41) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL2822931 | 0.68 | CNR1 (0.39) | KMT2AMEN1GABRA1GABRA5GABRA3 | |
| SCHEMBL3579839 | 0.67 | CNR1 (0.52) | KMT2AMEN1GABRA1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293730-B2 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | KNUST HENNER | 2010-03-25 | — | — | US | disclosed |
| US-7671048-B2 | Substituted imidazo [1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1809297-B1 | IMIDAZO[1,5A]TRIAZOLO[1,5D]BENZODIAZEPINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| EP-1807432-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
| US-20060079507-A1 | Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079507-A1 | Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | GABRA3, GABRA1, OXER1 | KMT2A 904/4885MEN1 3823/4885GABRA1 2/4885 |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | KMT2A 1762/4885MEN1 2911/4885GABRA1 1/4885 |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | GABRA1, GABRA5, ADRA1A | KMT2A 1766/4885MEN1 2474/4885GABRA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.